Saturday, July 11, 2026

pharma · No medical condition. · Breast cancer

George Institute for

George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER

Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Clinical program

Sustanon 250, solution injectable

Phase 2 · small molecule · Androgen deficiency, palliative care

Sustanon 250, solution injectable for Androgen deficiency, palliative care is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

← All The George Institute projects Phase 2 small molecule active

Internal code IJB-SP01-2025

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
The George Institute
Phase
Phase 2
Modality
small_molecule
Indication
Androgen deficiency, palliative care
Status
active
Trials
1